<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7454523\results\search\testTrace\results.xml">
  <result pre="National Health Service (NHS) no new cases of SARS CoV-1" exact="infection" post="have been reported in humans since 2004 (National Health"/>
  <result pre="variable, ranging from no symptoms to mild upper respiratory tract" exact="infection" post="to respiratory failure (Zhou etÂ al. 2020), upper respiratory"/>
  <result pre="possible that an interferon-gamma (IFN-Î³) mediated cytokine storm after SARS" exact="infection" post="is the culprit (Huang etÂ al. 2005). In fact,"/>
  <result pre="Although liver dysfunction has been reported in COVID-19 patients, its" exact="prevalence" post="seems much lower; only 3/80 (3.75%) of patients in"/>
  <result pre="frontal, temporal, parietal lobes. Arabi et al did not report" exact="virus detection" post="in brain tissue or CSF but noted that the"/>
  <result pre="temporal, parietal lobes. Arabi et al did not report virus" exact="detection" post="in brain tissue or CSF but noted that the"/>
  <result pre="of central neurogenic respiratory failure in the setting of coronavirus" exact="infection" post="is supported by some evidence from animal models (Li"/>
  <result pre="SARS-CoV-1 particles could enter the brain via intranasal inoculation. The" exact="infection" post="propagated from the sinuses to the olfactory bulb. Once"/>
  <result pre="propagated from the sinuses to the olfactory bulb. Once the" exact="infection" post="of the olfactory bulb was established, the infection spread"/>
  <result pre="Once the infection of the olfactory bulb was established, the" exact="infection" post="spread throughout the brain to reach the medullary respiratory"/>
  <result pre="their concentration in lung tissue. In this experiment, establishing an" exact="infection" post="of the sinuses may have been essential because hematogenous"/>
  <result pre="could occur once mice were inoculated with MERS-CoV intranasally; the" exact="infection" post="showed a predilection for the thalamus and brainstem (the"/>
  <result pre="and Levy 2020); these findings may appear in early COVID-19" exact="infection" post="even when there is no clinically identifiable bleeding. Interestingly,"/>
  <result pre="mechanism of viral-mediated direct endothelial insult, inflammatory mediators of COVID-19" exact="infection" post="may have a pivotal role in the pathogenesis of"/>
  <result pre="etÂ al. 2020). In addition, lung damage related to COVID-19" exact="infection" post="has been associated with lymphocytic infiltrates, thus providing evidence"/>
  <result pre="explain the efficacy of certain immune modulator drugs in the" exact="treatment" post="of severe COVID-19 cases. Since the outset of the"/>
  <result pre="Stroud etÂ al. 2019), might have promising results in the" exact="treatment" post="of COVID-19. Currently, clinical trials of Tocilizumab (Chinese Clinical"/>
  <result pre="al. 2020). Other immune-modulating medications were also considered in the" exact="treatment" post="of COVID-19, after evidence of immune-mediated damage emerged. Hydroxychloroquine,"/>
  <result pre="among them. This malaria-prophylaxis drug, previously proven effective in the" exact="treatment" post="of autoimmune diseases such as systemic lupus erythematous (SLE;"/>
  <result pre="clinical trials. The resulting evidence for its efficacy in the" exact="treatment" post="of COVID-19 infection was contradictory: Results from some trials"/>
  <result pre="resulting evidence for its efficacy in the treatment of COVID-19" exact="infection" post="was contradictory: Results from some trials suggested that hydroxychloroquine"/>
  <result pre="al.Development and validation of the HScore, a score for the" exact="diagnosis" post="of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613â€&quot;20.24782338 FaureE, PoissyJ,"/>
  <result pre="syndrome?Rhinol. 2020;58:3â€&quot;0. GautretP, LagierJ, ParolaPet al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
  <result pre="Respir Med. 2020;8. JossetL, MenacheryVD, GralinskiLEet al.Cell host response to" exact="infection" post="with novel human coronavirus EMC predicts potential antivirals and"/>
  <result pre="Antimicrob Agents. 2020;55:105924.32081636 LauKK, YuWC, ChuCMet al.Possible central nervous system" exact="infection" post="by SARS coronavirus. Emerg Infect Dis. 2004;10:342â€&quot;4.15030709 LechienJ, Chiesa-EstombaC,"/>
  <result pre="October 24. NetlandJ, MeyerholzDK, MooreSet al.Severe acute respiratory syndrome coronavirus" exact="infection" post="causes neuronal death in the absence of encephalitis in"/>
  <result pre="Dis. 2010;69:20â€&quot;8.19103632 RussellCD, MillarJE, BaillieJKClinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injury. Lancet. 2020;395:473â€&quot;5.32043983 SaadM, OmraniAS, BaigKet"/>
  <result pre="2014;29:301â€&quot;6. SampathkumarP, TemesgenZ, SmithTFet al.SARS: epidemiology, clinical presentation, management, and" exact="infection" post="control measures. Mayo Clin Proc. 2003;78:882â€&quot;90.12839084 SaperVE, ChenG, DeutschGHet"/>
  <result pre="(SARS). J Clin Pathol. 2004;57:260â€&quot;5.14990596 VargaZ, FlammerA, SteigerPet al.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19. Lancet. 2020;395:1417â€&quot;8.32325026 collab: Viruses ICoTo"/>
 </snippets>
</snippetsTree>
